Last reviewed · How we verify
PB1046 Subcutaneous Injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PB1046 Subcutaneous Injection (PB1046 Subcutaneous Injection) — PhaseBio Pharmaceuticals Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PB1046 Subcutaneous Injection TARGET | PB1046 Subcutaneous Injection | PhaseBio Pharmaceuticals Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PB1046 Subcutaneous Injection CI watch — RSS
- PB1046 Subcutaneous Injection CI watch — Atom
- PB1046 Subcutaneous Injection CI watch — JSON
- PB1046 Subcutaneous Injection alone — RSS
Cite this brief
Drug Landscape (2026). PB1046 Subcutaneous Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/pb1046-subcutaneous-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing